Cargando…
Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?
SARS-CoV-2 is a positive-sense single-stranded RNA virus that causes the COVID-19 infection. Spike proteins are the most important proteins found on its capsule using the host’s ACE2 receptors to invade respiratory cells. The natural course of the COVID-19 infection is variable, from asymptomatic to...
Autores principales: | Pelechas, Eleftherios, Drossou, Vassiliki, Voulgari, Paraskevi V., Drosos, Alexandros A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Mediterranean Journal of Rheumatology (MJR)
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656133/ https://www.ncbi.nlm.nih.gov/pubmed/33196003 http://dx.doi.org/10.31138/mjr.31.3.259 |
Ejemplares similares
-
Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients
por: Pelechas, Eleftherios, et al.
Publicado: (2022) -
Colchicine Against SARS-CoV-2 Infection: What is the Evidence?
por: Drosos, Alexandros A., et al.
Publicado: (2022) -
A Response to: Letter to the Editor Regarding the Article: “Colchicine Against SARS-CoV-2 Infection: What is the Evidence?”
por: Drosos, Alexandros A., et al.
Publicado: (2022) -
COVID-19 in patients with gout on colchicine
por: Pelechas, Eleftherios, et al.
Publicado: (2021) -
Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience
por: Migkos, Michalis P., et al.
Publicado: (2021)